Octogenarian Newly Diagnosed Multiple Myeloma Patients Without Geriatric Impairments: The Role of Age >80 in the IMWG Frailty Score

SUPPLEMENTARY APPENDIX

- **Table S1**. Treatment received by Frail_by_age and Frail_by_other patients

- **Table S2**. Treatment discontinuation details

- **Figure S1**. PFS (A) and PFS2 (B) of Frail_by_age vs. Frail_by_other patients. No_frail patients are shown as reference.

- **Figure S2**. Time to protocol discontinuation (end of treatment) of Frail_by_age vs. Frail_by_other patients. No_frail patients are shown as reference.

- **Figure S3**. Cumulative incidence of grade ≥3 non-hematologic (A) and hematologic (B) adverse events

- **Figure S4**. OS of patients aged ≤80 years (A) and >80 years (B) according to the presence or absence of geriatric impairments

Table S1. Treatment received by Frail_by_age and Frail_by_other patients

| Treatment	Frail_by_age N=70 (%)	Frail_by_other N=190 (%)
CCD	2 (3)	8 (4)
CPR	12 (17)	42 (22)
MPR	16 (23)	33 (17)
Rd	20 (29)	45 (24)
VMP	6 (9)	19 (10)
VCP	3 (4)	16 (8)
VP	11 (16)	27(14)

Abbreviations. CCD, carfilzomib-cyclophosphamide-dexamethasone; CPR, cyclophosphamide-prednisone-lenalidomide; MPR, melphalan-prednisone-lenalidomide; Rd, lenalidomide-low-dose dexamethasone; VMP, bortezomib-melphalan-prednisone; VCP, bortezomib-cyclophosphamide-prednisone; VP, bortezomib-low-dose prednisone.

Table S2. Treatment discontinuation details

| Discontinuation	Frail_by_age N=70 (%)	Frail_by_other N=190 (%)	No_frail N=609 (%)
Adverse event	42 (60)	88 (46)	215 (35)
Hematologic	5 (7)	8 (4)	27 (4)
Dermatologic	4 (6)	2 (1)	22 (4)
Infections	3 (4)	12 (6)	12 (2)
Cardiac	3 (4)	8 (4)	13 (2)
Neurologic	2 (3)	4 (2)	10 (2)
Progressive disease	23 (33)	91 (48)	313 (51)
Other	5 (7)	11 (6)	81 (13)

Figure S1. PFS (A) and PFS2 (B) of Frail_by_age vs. Frail_by_other patients. No_frail patients are shown as reference.

A. PFS

No_frail	609	452	301	224	179	141	112	61
Frail_by_other	190	114	68	46	34	25	17	9
Frail_by_age	70	48	31	17	12	9	8	4

Number at risk

B. PFS2

No_frail	609	541	452	367	304	241	199	108
Frail_by_other	190	135	95	75	65	45	32	17
Frail_by_age	70	54	42	30	25	20	19	7

Number at risk

Abbreviations. PFS, progression-free survival; PFS2, progression-free survival-2; HR, hazard ratio; CI, confidence interval; p, p-value.

3

Figure S2. Time to protocol discontinuation (end of treatment) of Frail_by_age vs. Frail_by_other patients. No_frail patients are shown as reference.

End of treatment

Frail_by_age vs. No_frail: HR 1.34, 95% CI 1.03-1.74, p=0.030
Frail_by_other vs. No_frail: HR 1.25, 95% CI 1.04-1.49, p=0.016
Frail_by_age vs. Frail_by_other: HR 1.07, 95% CI 0.81-1.43, p=0.632

No_frail	609	431	291	203	147	104	81	44
Frail_by_other	190	107	65	42	28	17	12	7
Frail_by_age	70	40	25	15	9	8	5	2

Number at risk

Abbreviations. HR, hazard ratio; CI, confidence interval; p, p-value.

Figure S3. Cumulative incidence of grade ≥3 non-hematologic (A) and hematologic (B) adverse events

A. Grade ≥3 non-hematologic adverse events

Frail_by_age vs. **No_frail**: HR 0.94, 95% CI 0.57-1.53, p=0.793
Frail_by_other vs. **No_frail**: HR 1.37, 95% CI 1.02-1.84, p=0.036
Frail_by_age vs. **Frail_by_other**: HR 0.68, 95% CI 0.40-1.15, p=0.151

No_frail	609	375	245	176	138	104	89	49
Frail_by_other	190	74	42	26	16	13	8	4
Frail_by_age	70	36	24	14	9	7	6	3

Number at risk

B. Grade ≥3 hematologic adverse events

Frail_by_age vs. **No_frail**: HR 0.97, 95% CI 0.63-1.51, p=0.904
Frail_by_other vs. **No_frail**: HR 0.99, 95% CI 0.74-1.33, p=0.950
Frail_by_age vs. **Frail_by_other**: HR 0.98, 95% CI 0.60-1.61, p=0.944

|							
No_frail	609	301	198	149	127	98	72	37
Frail_by_other	190	69	34	26	19	13	8	2
Frail_by_age	70	34	21	13	8	5	5	2

Number at risk

Abbreviations. HR, hazard ratio; CI, confidence interval; p, p-value.

Figure S4. OS of patients aged ≤80 years (A) and >80 years (B) according to the presence or absence of geriatric impairments

A. OS: age ≤80 years

B. OS: age >80 years

Abbreviations. OS, overall survival; HR, hazard ratio; CI, confidence interval; p, p-value.